BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/11/2015 5:56:00 PM | Browse: 1966 | Download: 2443
 |
Received |
|
2014-03-26 08:30 |
|
Peer-Review Started |
|
2014-03-26 16:42 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2014-05-03 19:35 |
|
Revised |
|
2014-07-31 07:07 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2014-09-19 08:50 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2014-09-19 09:33 |
|
Articles in Press |
|
2014-09-19 10:23 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2015-01-29 18:24 |
|
Publish the Manuscript Online |
|
2015-02-11 17:56 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Michael S Broder, David Beenhouwer, Jonathan R Strosberg, Maureen P Neary and Dasha Cherepanov |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936-1080, United States |
|
|
| Corresponding Author |
Michael S Broder, MD, MSHS, Partnership for Health Analytic Research, LLC, 280 South Beverly Drive, Suite 404, Beverly Hills, CA 90212, United States. mbroder@pharllc.com |
| Key Words |
Carcinoma; Neuroendocrine; Carcinoid syndrome; Carcinoid tumor; Gastrointestinal neoplasms; Neuroendocrine tumor; Antineoplastic agents; Hormonal; Dose-Response relationship; Drug; Octreotide; Literature review; Efficacy; Effectiveness; Symptom control; Tumor progression control; Diarrhea; Abdominal pain; Flushing |
| Core Tip |
Although octreotide-long-acting repeatable (LAR) is Food and Drug Administration approved for alleviating severe diarrhea/flushing associated with metastatic carcinoid tumors at doses ≤ 30 mg every 4 wk, our review found that several studies within the published literature described the use of above-label doses of octreotide-LAR for symptom and tumor control of neuroendocrine tumors. Expert clinical opinion, as reported in this review, supports escalation of somatostatin analogs for patients with refractory hormonal symptoms. |
| Publish Date |
2015-02-11 17:56 |
| Citation |
Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: A systematic literature review. World J Gastroenterol 2015; 21(6): 1945-1955 |
| URL |
http://www.wjgnet.com/1007-9327/full/v21/i6/1945.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v21.i6.1945 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
